[go: up one dir, main page]

MX2021005607A - Stabilized pre-fusion rsv f proteins. - Google Patents

Stabilized pre-fusion rsv f proteins.

Info

Publication number
MX2021005607A
MX2021005607A MX2021005607A MX2021005607A MX2021005607A MX 2021005607 A MX2021005607 A MX 2021005607A MX 2021005607 A MX2021005607 A MX 2021005607A MX 2021005607 A MX2021005607 A MX 2021005607A MX 2021005607 A MX2021005607 A MX 2021005607A
Authority
MX
Mexico
Prior art keywords
proteins
fusion rsv
stabilized pre
rsv
stabilized
Prior art date
Application number
MX2021005607A
Other languages
Spanish (es)
Inventor
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2021005607A publication Critical patent/MX2021005607A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides stable pre-fusion respiratory syncytial virus (RSV) F proteins, immunogenic compositions comprising said proteins and uses thereof for the prevention and/or treatment of RSV infection.
MX2021005607A 2018-11-13 2019-11-12 Stabilized pre-fusion rsv f proteins. MX2021005607A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18205863 2018-11-13
PCT/EP2019/080989 WO2020099383A1 (en) 2018-11-13 2019-11-12 Stabilized pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
MX2021005607A true MX2021005607A (en) 2021-06-30

Family

ID=64308587

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005607A MX2021005607A (en) 2018-11-13 2019-11-12 Stabilized pre-fusion rsv f proteins.

Country Status (20)

Country Link
US (1) US20220017574A1 (en)
EP (1) EP3880243A1 (en)
JP (1) JP2022513025A (en)
KR (1) KR20210091749A (en)
CN (1) CN113164583A (en)
AU (1) AU2019377989A1 (en)
BR (1) BR112021008975A2 (en)
CA (1) CA3117275A1 (en)
CL (1) CL2021001212A1 (en)
CO (1) CO2021006308A2 (en)
CR (1) CR20210306A (en)
EA (1) EA202191355A1 (en)
EC (1) ECSP21042554A (en)
IL (1) IL282892A (en)
JO (1) JOP20210106A1 (en)
MX (1) MX2021005607A (en)
PE (1) PE20211469A1 (en)
PH (1) PH12021550974A1 (en)
SG (1) SG11202104522UA (en)
WO (1) WO2020099383A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017027448A2 (en) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv rsv vaccine
KR102401247B1 (en) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Vaccine against RSV
EP3464331B1 (en) 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP4294436A1 (en) * 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
JP2024536236A (en) * 2021-09-29 2024-10-04 エスケー バイオサイエンス カンパニー リミテッド Recombinant live attenuated RSV vaccine and method for its production
CN115850396B (en) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 RSV nanoparticle vaccine and preparation method and application thereof
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
CN117304279B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof
CN117304280B (en) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 Recombinant RSV F protein and application thereof
CN117777251B (en) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 RSV nanoparticle vaccine and preparation method thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2164860A2 (en) * 2007-06-06 2010-03-24 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP3508505A1 (en) 2007-12-24 2019-07-10 ID Biomedical Corporation of Quebec Recombinant rsv antigens
KR20120093811A (en) 2009-06-24 2012-08-23 아이디 바이오메디컬 코포레이션 오브 퀘벡 vaccine
US9492531B2 (en) 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
DK2464664T3 (en) * 2009-08-13 2016-01-18 Crucell Holland Bv ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT
MX343298B (en) 2010-07-09 2016-11-01 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use.
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US10232032B2 (en) * 2013-03-14 2019-03-19 Emory University Recombinant RSV with silent mutations, vaccines, and methods related thereto
EP2988780B1 (en) 2013-04-25 2018-12-26 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion rsv f polypeptides
KR102313153B1 (en) * 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble pre-fusion rsv f polypeptides
WO2016040556A1 (en) * 2014-09-12 2016-03-17 Rsv Corporation Virosomes containing respiratory syncytial virus strain line 19 fusion protein and uses thereof
BR112017027448A2 (en) * 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv rsv vaccine
KR20180026734A (en) * 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble fusion-pre-RSV F polypeptide
KR20180085730A (en) * 2015-10-29 2018-07-27 에모리 유니버시티 Chimeric RSV, immunogenic compositions, and methods of use
JP6817307B2 (en) * 2015-12-23 2021-01-20 ファイザー・インク RSVF protein mutant
CA3015570A1 (en) * 2016-03-29 2017-10-05 Peter Kwong Substitutions-modified prefusion rsv f proteins and their use
KR20220041966A (en) 2016-04-05 2022-04-01 얀센 백신스 앤드 프리벤션 비.브이. Stabilized soluble pre-fusion rsv f proteins
EP3464331B1 (en) * 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins

Also Published As

Publication number Publication date
CR20210306A (en) 2021-07-22
PE20211469A1 (en) 2021-08-05
AU2019377989A1 (en) 2023-10-05
CO2021006308A2 (en) 2021-05-31
PH12021550974A1 (en) 2022-05-02
ECSP21042554A (en) 2021-11-30
EP3880243A1 (en) 2021-09-22
CN113164583A (en) 2021-07-23
JOP20210106A1 (en) 2023-01-30
JP2022513025A (en) 2022-02-07
CL2021001212A1 (en) 2021-10-22
BR112021008975A2 (en) 2021-08-17
SG11202104522UA (en) 2021-05-28
US20220017574A1 (en) 2022-01-20
IL282892A (en) 2021-06-30
WO2020099383A1 (en) 2020-05-22
EA202191355A1 (en) 2021-09-20
KR20210091749A (en) 2021-07-22
CA3117275A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
MX2021005607A (en) Stabilized pre-fusion rsv f proteins.
MX2022015257A (en) Stabilized soluble pre-fusion rsv f proteins.
MY201791A (en) Stabilized soluble pre-fusion rsv f polypeptides
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
EA201890235A1 (en) STABILIZED SOLUBLE RSV F-POLYPEPTIDES TO MERGER
PH12015502735B1 (en) Stabilized soluble pre-fusion rsv f polypeptides
EA201070794A1 (en) Recombinant antigens RSV
PH12017501534A1 (en) Antiviral compounds
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
MX2012000035A (en) Recombinant rsv antigens.
PH12021552736A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
MX2021004356A (en) Formulations of anti-rsv antibodies and methods of use thereof.
MX2021006138A (en) Further heteroaromatic compounds having activity against rsv.
MX2023009738A (en) STABILIZED PRE-FUSION RSV F<sub>B</sub> ANTIGENS.